金水宝胶囊联合布地奈德福莫特罗对稳定期COPD患者炎症及T淋巴细胞因子的影响

Effects of Jinshuibao Capsule and Budesonide Formoterol on Inflammation and T Lymphocyte Factor in Stable COPD Patients

目的探讨金水宝胶囊联合布地奈德福莫特罗对稳定期慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者炎症及T淋巴细胞因子的影响。方法选择2017年1月至2019年1月于本院接受治疗的稳定期COPD患者共90例,随机分为观察组(45例)和对照组(45例)。对照组采用布地奈德福莫特罗治疗,观察组在对照组基础上联合金水宝胶囊治疗。对比两组患者治疗前后的肺功能指标[第1秒用力呼气量占用力肺活量的比值(第1秒用力呼气量(FEV1)/用力肺活量(FVC)、FEV 1、呼气峰值流量(PEF)]、炎症因子[细胞间黏附分子1(ICAM-1)、白细胞介素8(IL-8),肿瘤坏死因子α(TNF-α)]、血气指标[血氧分压(partial arterial oxygen pressure,PaO 2)、二氧化碳分压(arterial blood partial pressure of carbon dioxide,PaCO 2)]与T淋巴细胞亚群(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+)水平。结果治疗结束时,观察组FEV1/FVC、FEV1、PEF水平[(84.25±3.56)%、2.80±0.42 L、3.48±0.41L/s)]高于对照组[(75.35±3.42%)、2.52±0.41 L、2.64±0.35 L/s)],差异具有统计学意义(P<0.05)。观察组ICAM-1、IL-8、TNF-α水平(49.05±4.56ng/L、11.18±2.18μg/L、4.58±0.41μg/L)低于对照组(57.15±5.42 ng/L、15.03±2.95μg/L、6.24±1.65μg/L),差异具有统计学意义(P<0.05)。观察组PaO 2水平(72.15±12.36 mmHg)高于对照组(62.55±10.42mmHg),PaCO 2水平(30.74±8.38mmHg)则低于对照组(40.48±9.35mmHg),差异具有统计学意义(P<0.05)。观察组患者CD4^+、CD3^+、CD4^+/CD8^+水平[(41.18±3.18)%、(62.05±4.66)%、1.94±0.34]高于对照组[(36.33±2.95)%、(56.15±4.42)%、1.43±0.22],CD8^+水平[(21.18±1.41)%]低于对照组[(25.34±1.65)%],差异具有统计学意义(P<0.05)。结论金水宝胶囊联合布地奈德福莫特罗可有效改善稳定期COPD患者的肺功能,减轻机体炎症反应,提升免疫功能。

Objective To investigate the effects of Jinshuibao capsule combined with budesonide formoterol on inflammation and T lymphocyte factors in patients with stable chronic obstructive pulmonary disease(COPD).Methods Ninety stable COPD patients treated in our hospital from January,2017 to January,2019 were randomly divided into the observation group(45 cases)and the control group(45 cases).The control group was treated with budesonide formoterol,while the observation group was treated with Jinshuibao Capsule on the basis of the control group.The lung function indexes[ratio of forced expiratory volume in the first second(FEV1)/forced vital capacity(FVC),FEV1,peak expiratory flow(PEF)],inflammatory factors[intercellular adhesion molecule(ICAM-1),interleukin-8(IL-8),tumor necrosis factor-alpha(TNF-alpha)],blood gas finger were compared between the two groups before and after the treatment,as well as blood gas indexes[Partial arterial oxygen pressure(PaO 2),Arterial blood partial pressure of carbon dioxide(PaCO 2)]and T lymphocyte subsets(CD3^+,CD4^+,CD8^+,CD4^+/CD8^+)levels.Results At the end of treatment,the levels of FEV1/FVC,FEV1 and PEF in the observation group[(84.25±3.56)%,(2.80±0.42)L,(3.48±0.41)L/s]were higher than those in the control group[(75.35±3.42)%,(2.52±0.41)L,(2.64±0.35)L/s],with significant differences(all P<0.05).The levels of ICAM-1,IL-8 and TNF-alpha(49.05±4.56μg/L,11.18±2.18μg/L,4.58±0.41μg/L)in the observation group were lower than those in the control group(57.15±5.42μg/L,15.03±2.95μg/L,6.24±1.65μg/L),with significant differences(all P<0.05).The PaO 2 level(72.15±12.36mmHg)in the observation group was higher than that in the control group(62.55±10.42mmHg),while the PaCO 2 level(30.74±8.38mmHg)in the observation group was lower than that in the control group(40.48±9.35mmHg)(P<0.05).The levels of CD4^+,CD3^+,CD4^+/CD8^+in the observation group[(41.18±3.18)%,(62.05±4.66)%,1.94±0.34]were higher than those in the control group[(36.33±2.95)%,(56.15±4.42)%,1.43±0.22],and the levels of CD8^+in the observation group[(21.18±1.41)%]were lower than those in the control group[(25.34±1.65)%],all P<0.05.Conclusion Jinshuibao capsule combined with budesonide formoterol can effectively improve pulmonary function,alleviate inflammation and enhance immune function in stable COPD patients.